Vice President, Regulatory Affairs and Quality Assurance
Barbara M. Finn has served as our Vice President, Regulatory Affairs and Quality Assurance since September 2013. Ms. Finn has over 40 years of experience in the pharmaceutical industry. Prior to joining Otonomy, she served as the Senior Vice President of Regulatory Affairs and Quality Assurance at Sonexa, a private biotech company, where she had primary responsibility for interactions with the FDA and other regulatory authorities related to the company’s Alzheimer’s disease program. Previously, Ms. Finn served as Vice President, Regulatory Affairs and Quality Assurance at Neurocrine Biosciences, Inc., where she supported programs for insomnia, endometriosis, multiple sclerosis, and glioblastoma, and held various leadership positions as a regulatory affairs consultant at Quintiles, Inc. She began her career at Ciba-Geigy (now Novartis) where she spent 13 years in various roles starting as a research scientist in medicinal chemistry, transitioning to clinical research and then regulatory affairs. She is a past instructor in the SDSU Regulatory Science program. Ms. Finn received her Bachelor’s degree in Chemistry from the College of St. Elizabeth in Convent Station, New Jersey.